News

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience

According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema.

At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring treatment stability.

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting.

In cases with optic nerve hyperfluorescence or neurologic symptoms, prompt neuroimaging is warranted to rule out neuro-Behcet disease and guide multidisciplinary management.

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation.

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

The first SightLine meeting, held pre-ASCRS, reveals insights on physician-industry relationships, mentorship opportunities, and the practical applications of AI in healthcare.